Skip to main content

Xenon Pharmaceuticals Inc(XENE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low36.65
Day High37.58
Open:37.03
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest News

Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire - Tue Aug 9, 3:01PM CDT
Globe Newswire
Tue Aug 9, 3:01PM CDT
Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year Cash runway extended into 2026 following successful...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update
Globe Newswire - Tue Aug 2, 3:01PM CDT
Globe Newswire
Tue Aug 2, 3:01PM CDT
BURNABY, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company,...
Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022
Globe Newswire - Mon Jul 11, 3:01PM CDT
Globe Newswire
Mon Jul 11, 3:01PM CDT
BURNABY, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company,...

Latest Articles

Xenon Pharmaceuticals posts loss of $3.9 million in fourth quarter
Initial public offerings scheduled to debut next week
No pain
Surviving the perils of a life without pain
Surviving the perils of a life without pain
Xenon arranges financing for clinical development
AnorMed battle
Simon Pimstone, 37